Metycor (Metyrapone)

Metyrapone blocks the enzyme 11‑beta‑hydroxylase (CYP11B1) in the adrenal cortex, preventing the final conversion of 11‑deoxycortisol to cortisol. This inhibition reduces circulating cortisol, allowing clinicians to assess adrenal reserve or manage conditions of cortisol excess.

The dose of Metycor is individualized. A qualified prescriber determines the appropriate amount and dosing schedule based on the patient’s clinical condition, laboratory results, and response to therapy. No fixed regimen is provided here.

Safety data for Metyrapone during pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, so it should only be used when the potential benefit justifies the possible risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The most common alternative for cortisol reduction is ketoconazole, an antifungal that also inhibits steroid synthesis but through multiple enzymes. Metyrapone is more selective for 11‑beta‑hydroxylase, often resulting in fewer drug‑interaction concerns, whereas ketoconazole carries a higher risk of hepatic toxicity and broader enzyme inhibition.

Metycor tablets should be stored at room temperature, below 25 °C, in their original packaging. Keep them away from moisture, direct sunlight, and excessive heat to maintain potency throughout the shelf life.

Metycor is taken orally as a tablet. It should be swallowed whole with a glass of water, preferably on an empty stomach unless the prescriber advises otherwise. The exact timing relative to meals is determined by the treating physician.

Serious adverse events include acute adrenal insufficiency, severe hypotension, allergic reactions such as rash or angioedema, hepatic dysfunction, and significant electrolyte disturbances like hyponatremia or hypokalemia. Patients should seek immediate medical attention if any of these occur.

Metycor is contraindicated in patients with known hypersensitivity to Metyrapone or any tablet excipients, and it should be avoided in individuals with uncontrolled adrenal insufficiency, severe hepatic impairment, or those receiving high‑dose glucocorticoid therapy that could mask adrenal crisis.